PMID- 20043592
OWN - NLM
STAT- MEDLINE
DCOM- 20100219
LR  - 20161125
IS  - 0033-2240 (Print)
IS  - 0033-2240 (Linking)
VI  - 66
IP  - 8
DP  - 2009
TI  - [Homocysteine and asymmetric dimethylarginine (ADMA) in epilepsy].
PG  - 448-52
AB  - Homocysteine (Hcy) is a thyol amino acid resulting from demethylation of 
      methionine. It is metabolized through two pathways: remethylation and 
      trassulfuration, which use as cofactors folate, vitamin B6 and vitamin B12. 
      Hyperhomocysteinemia (hHcy) is a risk factor for cerebrovascular disease, 
      dementia, inborn defects, impaired cognitive function. Several drugs may change 
      metabolic pathways of Hcy, leading to an alteration of plasma Hcy levels. HHcy 
      has been documented in epileptic patients after chronic treatment with 
      antiepileptic drugs (carbamazepine, valproate). HHcy may lead to increase of the 
      level of asymmetric dimethylarginine (ADMA). ADMA has been identified as a 
      potential risk factor for cardiovascular disease and endothelial dysfunction. 
      ADMA is a product of methylation of L-arginine and endogenous nitric oxide (NO) 
      synthase inhibitor, and regulator of NO production. NO plays a role in the 
      convulsant effect. Supplementation of B vitamins, folate and L-arginine is a 
      strategy to reduce Hcy levels in patients with epilepsy treatment antiepileptic 
      drugs.
FAU - Dorszewska, Jolanta
AU  - Dorszewska J
AD  - Pracownia Neurobiologii Katedry Neurologii Uniwersytetu Medycznego im. Karola 
      Marcinkowskiego, Poznan. dorszewskaj@yahoo.com
FAU - Winczewska-Wiktor, Anna
AU  - Winczewska-Wiktor A
FAU - Sniezawska, Aleksandra
AU  - Sniezawska A
FAU - Kaczmarek, Izabela
AU  - Kaczmarek I
FAU - Steinborn, Barbara
AU  - Steinborn B
LA  - pol
PT  - Journal Article
PT  - Review
TT  - Homocysteina i asymetryczna dimetyloarginina (ADMA) w padaczce.
PL  - Poland
TA  - Przegl Lek
JT  - Przeglad lekarski
JID - 19840720R
RN  - 0 (Anticonvulsants)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 33CM23913M (Carbamazepine)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - 63CV1GEK3Y (N,N-dimethylarginine)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
SB  - IM
MH  - Anticonvulsants/therapeutic use
MH  - Arginine/*analogs & derivatives/metabolism
MH  - Carbamazepine/therapeutic use
MH  - Epilepsy/*drug therapy/*metabolism
MH  - Homocysteine/*metabolism
MH  - Humans
MH  - Nitric Oxide/biosynthesis
MH  - Nitric Oxide Synthase/antagonists & inhibitors
MH  - Valproic Acid/therapeutic use
RF  - 68
EDAT- 2010/01/02 06:00
MHDA- 2010/02/20 06:00
CRDT- 2010/01/02 06:00
PHST- 2010/01/02 06:00 [entrez]
PHST- 2010/01/02 06:00 [pubmed]
PHST- 2010/02/20 06:00 [medline]
PST - ppublish
SO  - Przegl Lek. 2009;66(8):448-52.